cathepsin L pseudogene 3Genealiases: CTSL1P3 · CTSLL3
Q-omics provides the consensus-scored CTSLP3 profile across patient tissues and cancer cell-line models. CTSLP3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CTSLP3 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CTSLP3 RNA expression shows 16,962 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KICH, and THYM as cancer lineages where CTSLP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTSLP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTSLP3 survival associations across molecular data types. CTSLP3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTSLP3 RNA expression–survival associations across cancer types. High CTSLP3 expression shows unfavorable associations in COAD, ACC and THCA, but favorable associations in LGG, UVM and READ. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for CTSLP3 RNA expression.
This table summarizes CTSLP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CTSLP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTSLP3 shows lower tumor expression in KICH, THCA, KIRC, BRCA and UCEC and higher tumor expression in LIHC. The KICH box plot shows higher CTSLP3 RNA expression in normal versus tumor tissue (log2 FC = −1.054, t-test p < 0.001).
This table shows molecular features associated with CTSLP3 in patient tissues and cancer cell lines. In patient samples, CTSLP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
